Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin

Generated Narrative: Group

Resource Group "179786" Version "3" Updated "2023-12-04 20:30:40+0000"

Profile: ExposureDefinition

Artifact related artifact:

Artifact Title: ExposureDefinition: Therapeutic-dose anticoagulation with heparin

Artifact URL: https://fevir.net/resources/Group/179786

Artifact Publisher: Computable Publishing LLC

Artifact Copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

Artifact Contact: support@computablepublishing.com

Artifact Author: Brian S. Alper:

CombinationMethod: any-of

modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]

identifier: FEvIR Object Identifier/179786

type: animal

membership: definitional

name: ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin

description: Description: therapeutic-dose anticoagulation with heparin Note: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.

characteristic

CharacteristicDescription: ATTACC investigational arm

CharacteristicTiming

url

contextCode

value: Start of trial ()

url

offset

value: 0-14

url

text

value: Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen>24 hours, provided oxygen was required), whichever comes first.

code: Defined by CodeableConcept ()

value: Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels. ()

exclude: false

characteristic

CharacteristicDescription: ACTIV-4a investigational arm

CharacteristicTiming

url

contextCode

value: Start of trial ()

url

offset

value: 0-14

url

text

value: Up to 14 days or until hospital discharge, whichever comes first.

code: Defined by CodeableConcept ()

value: Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal. ()

exclude: false

characteristic

CharacteristicDescription: REMAP-CAP investigational arm

CharacteristicTiming

url

contextCode

value: Start of trial ()

url

offset

value: 0-14

url

text

value: Up to 14 days or until hospital discharge, whichever comes first.

code: Defined by CodeableConcept ()

value: Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels. ()

exclude: false